<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lopez J</submitter><funding>Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)</funding><funding>Generalitat de Catalunya (Government of Catalonia)</funding><pagination>91</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11889205</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>A one-two punch sequential regimen of senescence-inducing agents followed by senolytic drugs has emerged as a novel therapeutic strategy in cancer. Unfortunately, cancer cells undergoing therapy-induced senescence (TIS) vary widely in their sensitivity to senotherapeutics, and companion diagnostics to predict the response of TIS cancer cells to a specific senolytic drug are lacking. Here, we hypothesized that the ability of the BH3 profiling assay to functionally measure the mitochondrial priming state-the proximity to the apoptotic threshold-and the dependencies on pro-survival BCL-2 family proteins can be exploited to inform the sensitivity of TIS cancer cells to BH3-mimetics. Replicative, mitotic, oxidative, and genotoxic forms of TIS were induced in p16-null/p53-proficient, BAX-deficie</pubmed_abstract><journal>Cell death discovery</journal><pubmed_title>Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies.</pubmed_title><pmcid>PMC11889205</pmcid><funding_grant_id>CP20/00003</funding_grant_id><funding_grant_id>PI22/00297</funding_grant_id><funding_grant_id>CM22/00276</funding_grant_id><funding_grant_id>2022 INV-1 00001</funding_grant_id><pubmed_authors>Teixidor E</pubmed_authors><pubmed_authors>Cuyas E</pubmed_authors><pubmed_authors>Lopez-Bonet E</pubmed_authors><pubmed_authors>Menendez JA</pubmed_authors><pubmed_authors>Martin-Castillo B</pubmed_authors><pubmed_authors>Lopez J</pubmed_authors><pubmed_authors>Alarcon T</pubmed_authors><pubmed_authors>Verdura S</pubmed_authors><pubmed_authors>Lupu R</pubmed_authors><pubmed_authors>Llop-Hernandez A</pubmed_authors><pubmed_authors>Sardanyes J</pubmed_authors><pubmed_authors>Bosch-Barrera J</pubmed_authors><pubmed_authors>Martinez-Balibrea E</pubmed_authors><pubmed_authors>Serrano-Hervas E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies.</name><description>A one-two punch sequential regimen of senescence-inducing agents followed by senolytic drugs has emerged as a novel therapeutic strategy in cancer. Unfortunately, cancer cells undergoing therapy-induced senescence (TIS) vary widely in their sensitivity to senotherapeutics, and companion diagnostics to predict the response of TIS cancer cells to a specific senolytic drug are lacking. Here, we hypothesized that the ability of the BH3 profiling assay to functionally measure the mitochondrial priming state-the proximity to the apoptotic threshold-and the dependencies on pro-survival BCL-2 family proteins can be exploited to inform the sensitivity of TIS cancer cells to BH3-mimetics. Replicative, mitotic, oxidative, and genotoxic forms of TIS were induced in p16-null/p53-proficient, BAX-deficie</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2025-04-18T17:28:19.737Z</modification><creation>2025-04-07T04:58:42.991Z</creation></dates><accession>S-EPMC11889205</accession><cross_references><pubmed>40055336</pubmed><doi>10.1038/s41420-025-02379-y</doi></cross_references></HashMap>